- Home
- AIRS vs NYXH Comparison
AIRS vs NYXH Comparison
Compare AIRS & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- NYXH
- Stock Information
- Founded
- AIRS 2012
- NYXH 2009
- Country
- AIRS United States
- NYXH Belgium
- Employees
- AIRS N/A
- NYXH N/A
- Industry
- AIRS Medical/Nursing Services
- NYXH Medical/Dental Instruments
- Sector
- AIRS Health Care
- NYXH Health Care
- Exchange
- AIRS Nasdaq
- NYXH Nasdaq
- Market Cap
- AIRS 333.7M
- NYXH 394.1M
- IPO Year
- AIRS 2021
- NYXH 2021
- Fundamental
- Price
- AIRS $2.15
- NYXH $6.82
- Analyst Decision
- AIRS Hold
- NYXH Strong Buy
- Analyst Count
- AIRS 3
- NYXH 4
- Target Price
- AIRS $3.75
- NYXH $14.75
- AVG Volume (30 Days)
- AIRS 374.4K
- NYXH 81.7K
- Earning Date
- AIRS 03-14-2025
- NYXH 03-13-2025
- Dividend Yield
- AIRS N/A
- NYXH N/A
- EPS Growth
- AIRS N/A
- NYXH N/A
- EPS
- AIRS N/A
- NYXH N/A
- Revenue
- AIRS $180,350,000.00
- NYXH $4,680,609.00
- Revenue This Year
- AIRS N/A
- NYXH $504.18
- Revenue Next Year
- AIRS $5.63
- NYXH $149.52
- P/E Ratio
- AIRS N/A
- NYXH N/A
- Revenue Growth
- AIRS N/A
- NYXH 3.98
- 52 Week Low
- AIRS $2.05
- NYXH $6.76
- 52 Week High
- AIRS $9.20
- NYXH $13.50
- Technical
- Relative Strength Index (RSI)
- AIRS 25.18
- NYXH 23.12
- Support Level
- AIRS $2.58
- NYXH $10.26
- Resistance Level
- AIRS $2.91
- NYXH $11.87
- Average True Range (ATR)
- AIRS 0.32
- NYXH 0.77
- MACD
- AIRS 0.01
- NYXH -0.45
- Stochastic Oscillator
- AIRS 7.87
- NYXH 1.19
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.